130 related articles for article (PubMed ID: 10870640)
1. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
Horber DH; Cattaneo-Pangrazzi RM; von Ballmoos P; Schott H; Ludwig PS; Eriksson S; Fichtner I; Schwendener RA
J Cancer Res Clin Oncol; 2000 Jun; 126(6):311-9. PubMed ID: 10870640
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
Schott H; Schwendener RA
Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
[TBL] [Abstract][Full Text] [Related]
3. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Cattaneo-Pangrazzi RM; Schott H; Schwendener RA
Prostate; 2000 Sep; 45(1):8-18. PubMed ID: 10960838
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine.
Horber DH; von Ballmoos P; Schott H; Schwendener RA
Br J Cancer; 1995 Nov; 72(5):1067-73. PubMed ID: 7577448
[TBL] [Abstract][Full Text] [Related]
5. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Strasser S; Maier S; Leisser C; Saiko P; Madlener S; Bader Y; Bernhaus A; Gueorguieva M; Richter S; Mader RM; Wesierska-Gadek J; Schott H; Szekeres T; Fritzer-Szekeres M; Krupitza G
Differentiation; 2006 Dec; 74(9-10):488-98. PubMed ID: 17177846
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors.
Hunáková L; Suliková M; Duraj J; Sedlák J; Chorváth B
Neoplasma; 1996; 43(5):291-5. PubMed ID: 8996546
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
Schwendener RA; Schott H
J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Horber DH; Schott H; Schwendener RA
Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
Schwendener RA; Friedl K; Depenbrock H; Schott H; Hanauske AR
Invest New Drugs; 2001; 19(3):203-10. PubMed ID: 11561676
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
Horber DH; Schott H; Schwendener RA
Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
[TBL] [Abstract][Full Text] [Related]
11. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
Schwendener RA; Horber DH; Odermatt B; Schott H
J Cancer Res Clin Oncol; 1996; 122(2):102-8. PubMed ID: 8576276
[TBL] [Abstract][Full Text] [Related]
12. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.
Cai J; Damaraju VL; Groulx N; Mowles D; Peng Y; Robins MJ; Cass CE; Gros P
Cancer Res; 2008 Apr; 68(7):2349-57. PubMed ID: 18381442
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy.
Månsson E; Paul A; Löfgren C; Ullberg K; Paul C; Eriksson S; Albertioni F
Br J Haematol; 2001 Sep; 114(3):557-65. PubMed ID: 11552980
[TBL] [Abstract][Full Text] [Related]
14. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
Koller-Lucae SK; Schott H; Schwendener RA
J Pharmacol Exp Ther; 1997 Sep; 282(3):1572-80. PubMed ID: 9316874
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
[TBL] [Abstract][Full Text] [Related]
16. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
Niitsu N; Ishii Y; Matsuda A; Honma Y
Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
[TBL] [Abstract][Full Text] [Related]
17. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
Koller-Lucae SK; Schott H; Schwendener RA
Br J Cancer; 1999 Jul; 80(10):1542-9. PubMed ID: 10408395
[TBL] [Abstract][Full Text] [Related]
18. Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
Maier S; Strasser S; Saiko P; Leisser C; Sasgary S; Grusch M; Madlener S; Bader Y; Hartmann J; Schott H; Mader RM; Szekeres T; Fritzer-Szekeres M; Krupitza G
Apoptosis; 2006 Mar; 11(3):427-40. PubMed ID: 16538382
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Schwendener R; Schott H
Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
